676 related articles for article (PubMed ID: 16193110)
21. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
22. Energetics, conformation, and recognition of DNA duplexes modified by monodentate Ru(II) complexes containing terphenyl arenes.
Novakova O; Malina J; Suchankova T; Kasparkova J; Bugarcic T; Sadler PJ; Brabec V
Chemistry; 2010 May; 16(19):5744-54. PubMed ID: 20376825
[TBL] [Abstract][Full Text] [Related]
23. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
24. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.
Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ
Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536
[TBL] [Abstract][Full Text] [Related]
25. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
26. Selective cytotoxic Ru(II) arene Cp* complex salts [R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).
Loughrey BT; Healy PC; Parsons PG; Williams ML
Inorg Chem; 2008 Oct; 47(19):8589-91. PubMed ID: 18783214
[TBL] [Abstract][Full Text] [Related]
27. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
[TBL] [Abstract][Full Text] [Related]
28. In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin.
Deubel DV; Lau JK
Chem Commun (Camb); 2006 Jun; (23):2451-3. PubMed ID: 16758012
[TBL] [Abstract][Full Text] [Related]
29. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
30. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
31. Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development.
Babak MV; Meier SM; Legin AA; Adib Razavi MS; Roller A; Jakupec MA; Keppler BK; Hartinger CG
Chemistry; 2013 Mar; 19(13):4308-18. PubMed ID: 23341078
[TBL] [Abstract][Full Text] [Related]
32. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
[TBL] [Abstract][Full Text] [Related]
33. Ruthenium(II)-arene complexes with strong fluorescence: insight into the underlying mechanism.
Zhou Q; Lei W; Chen Y; Li C; Hou Y; Zhang B; Wang X
Chemistry; 2012 Jul; 18(28):8617-21. PubMed ID: 22700010
[No Abstract] [Full Text] [Related]
34. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
35. Deactivation of ruthenium olefin metathesis catalysts through intramolecular carbene-arene bond formation.
Vehlow K; Gessler S; Blechert S
Angew Chem Int Ed Engl; 2007; 46(42):8082-5. PubMed ID: 17854014
[No Abstract] [Full Text] [Related]
36. Ru(III)-based compounds with sulfur donor ligands: synthesis, characterization, electrochemical behaviour and anticancer activity.
Giovagnini L; Sitran S; Castagliuolo I; Brun P; Corsini M; Zanello P; Zoleo A; Maniero A; Biondi B; Fregona D
Dalton Trans; 2008 Dec; (47):6699-708. PubMed ID: 19153618
[TBL] [Abstract][Full Text] [Related]
37. Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro.
Kamatchi TS; Chitrapriya N; Lee H; Fronczek CF; Fronczek FR; Natarajan K
Dalton Trans; 2012 Feb; 41(7):2066-77. PubMed ID: 22183160
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents.
Lucas SJ; Lord RM; Wilson RL; Phillips RM; Sridharan V; McGowan PC
Dalton Trans; 2012 Dec; 41(45):13800-2. PubMed ID: 23015068
[TBL] [Abstract][Full Text] [Related]
39. Oligonuclear polypyridylruthenium(II) complexes incorporating flexible polar and non-polar bridges: synthesis, DNA-binding and cytotoxicity.
Mulyana Y; Weber DK; Buck DP; Motti CA; Collins JG; Keene FR
Dalton Trans; 2011 Feb; 40(7):1510-23. PubMed ID: 21218244
[TBL] [Abstract][Full Text] [Related]
40. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate.
Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ
J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
